THY1 and Parkinson disease: With their large variety of endpoints in multiple behavioral domains (e.g., motor, cognition, anxiety, olfaction, gastrointestinal) and wide range of molecular disturbances similar to those known or suspected to occur in the majority of PD patients (e.g., dopamine loss, striatal degeneration, microgliosis, mitochondrial deficits, alpha-synuclein aggregation), the Thy1-aSyn line 61 model is a useful tool to test novel therapeutic strategies (Figs. 2 and 3).